Genentech and Biogen roll the dice on an upstart biotech with a new siRNA approach — going deep into the brain for targets in neurodegeneration

Atalanta isn’t your average stealth biotech making a debut. They have some history and deals to sketch out in rough outlines.

The founding execs date …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Genen­tech and Bio­gen roll the dice on an up­start biotech with a new siR­NA ap­proach — go­ing deep in­to the brain for tar­gets in neu­rode­gen­er­a­tion